title: [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
authors.forename: Fei-jiao
authors.initials: FJ
authors.lastname: Ge
authors.forename: Jian-ming
authors.initials: JM
authors.lastname: Xu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D009369:Neoplasms / Q000188:drug therapy; D011507:Proteinuria / Q000139:chemically induced*; D013923:Thromboembolism / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001241:Aspirin